Targeting of syndecan-1 by microRNA miR-10b promotes breast cancer cell motility and invasiveness via a Rho-GTPase- and E-cadherin-dependent mechanism

International Journal of Cancer

Volumn 131, Issue 6, 2012, Pages

  Ibrahim, Sherif A ^a,b   Yip, George W ^c   Stock, Christian ^a   Pan, Jun Wei ^c   Neubauer, Claudia ^a   Poeter, Michaela ^d   Pupjalis, Danute ^d   Koo, Chuay Yeng ^c   Kelsch, Reinhard ^a   Schüle, Roland ^e   Rescher, Ursula ^d   Kiesel, Ludwig ^a   Götte, Martin ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b CAIRO UNIVERSITY   (Egypt)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d UNIVERSITY OF MÜNSTER   (Germany)

^e UNIVERSITY OF FREIBURG   (Germany)

Author keywords

ATF 2; breast cancer; CD138; cell motility; heparan sulfate proteoglycan; microRNA; oncomiR; RUNX1; syndecans

Indexed keywords

ACTIN GAMMA2; ACTIVATING TRANSCRIPTION FACTOR 2; CADHERIN 11; CLAUDIN 1; COLLAGEN TYPE 1; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLOOXYGENASE 2; FIBRONECTIN; FOCAL ADHESION KINASE; GELATINASE A; GELATINASE B; HEPARANASE; LAMININ; MEMBRANE PROTEIN; MICRORNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; PROTEIN MYL9; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; RHOC PROTEIN; SMALL INTERFERING RNA; SYNDECAN 1; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR RUNX1; TRANSGELIN 1; UNCLASSIFIED DRUG; UVOMORULIN; VINCULIN;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CELL ADHESION; CELL FUNCTION; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; FILOPODIUM; GENE OVEREXPRESSION; GENE SILENCING; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEPLETION; UPREGULATION;

ACTIVATING TRANSCRIPTION FACTOR 2; BREAST NEOPLASMS; CADHERINS; CELL COMMUNICATION; CELL LINE, TUMOR; CELL MOVEMENT; CORE BINDING FACTOR ALPHA 2 SUBUNIT; DISEASE PROGRESSION; FEMALE; HUMANS; MICRORNAS; NEOPLASM INVASIVENESS; PHOSPHORYLATION; RHO GTP-BINDING PROTEINS; RNA, MESSENGER; RNA, SMALL INTERFERING; SYNDECAN-1;

EID: 84864124537     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27629     Document Type: Article

References (50)

1. Yip GW, Smollich M, Götte M,. Therapeutic value of glycosaminoglycans in cancer. Mol Cancer Ther 2006; 5: 2139-48.
2. Götte M, Kersting C, Radke I, et al. An expression signature of syndecan-1 (CD138), E-cadherin and c-met is associated with factors of angiogenesis and lymphangiogenesis in ductal breast carcinoma in situ. Breast Cancer Res 2007; 9: R8.
3. Beauvais DM, Ell BJ, McWhorter AR, et al. Syndecan-1 regulates alphavbeta3 and alphavbeta5 integrin activation during angiogenesis and is blocked by synstatin, a novel peptide inhibitor. J Exp Med 2009; 206: 691-705.
4. Nikolova V, Koo CY, Ibrahim SA, et al. Differential roles for membrane-bound and soluble syndecan-1 (CD138) in breast cancer progression. Carcinogenesis 2009; 30: 397-407.
5. Maeda T, Desouky J, Friedl A,. Syndecan-1 expression by stromal fibroblasts promotes breast carcinoma growth in vivo and stimulates tumor angiogenesis. Oncogene 2006; 25: 1408-12.
6. McDermott SP, Ranheim EA, Leatherberry VS, et al. Juvenile syndecan-1 null mice are protected from carcinogen-induced tumor development. Oncogene 2007; 26: 1407-16.
7. Tokes AM, Szasz AM, Farkas A, et al. Stromal matrix protein expression following preoperative systemic therapy in breast cancer. Clin Cancer Res 2009; 15: 731-39.
8. Götte M, Kersting C, Ruggiero M, et al. Predictive value of syndecan-1 expression for the response to neoadjuvant chemotherapy of primary breast cancer. Anticancer Res 2006; 26: 621-7.
9. Barbareschi M, Maisonneuve P, Aldovini D, et al. High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis. Cancer 2003; 98: 474-83.
10. Leivonen M, Lundin J, Nordling S, et al. Prognostic value of syndecan-1 expression in breast cancer. Oncology 2004; 67: 11-8.
11. Loussouarn D, Campion L, Sagan C, et al. Prognostic impact of syndecan-1 expression in invasive ductal breast carcinomas. Br J Cancer 2008; 98: 1993-8.
12. Mennerich D, Vogel A, Klaman I, et al. Shift of syndecan-1 expression from epithelial to stromal cells during progression of solid tumours. Eur J Cancer 2004; 40: 1373-82.
13. Lofgren L, Sahlin L, Jiang S, et al. Expression of syndecan-1 in paired samples of normal and malignant breast tissue from postmenopausal women. Anticancer Res 2007; 27: 3045-50.
14. Hannafon BN, Sebastiani P, de las Morenas A, et al. Expression of microRNA and their gene targets are dysregulated in preinvasive breast cancer. Breast Cancer Res 2011; 13: R24.
15. Betel D, Koppal A, Agius P, et al. Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites. Genome Biol 2010; 11: R90.
16. Betel D, Wilson M, Gabow A, et al. The microRNA.org resource: targets and expression. Nucleic Acids Res 2008; 36: D149-153.
17. Götte M,. MicroRNAs in breast cancer pathogenesis. Minerva Ginecol 2010; 62: 559-65.
18. Bartel DP,. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-97.
19. Iorio MV, Ferracin M, Liu CG, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005; 65: 7065-70.
20. Ma L, Teruya-Feldstein J, Weinberg RA,. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2005; 449: 682-88.
21. Baffa R, Fassan M, Volinia S, et al. MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. J Pathol 2009; 219: 214-21.
22. Ma L, Reinhardt F, Pan E, et al. Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat Biotechnol 2010; 28: 341-7.
23. Shen X, Fang J, Lv X, et al. Heparin impairs angiogenesis through inhibition of microRNA-10b. J Biol Chem 2011; 286: 26616-27.
24. Götte M, Mohr C, Koo CY, et al. miR-145-dependent targeting of junctional adhesion molecule A and modulation of fascin expression are associated with reduced breast cancer cell motility and invasiveness. Oncogene 2010; 29: 6569-80.
25. Götte M, Spillmann D, Yip GW, et al. Changes in heparan sulfate are associated with delayed wound repair, altered cell migration, adhesion and contractility in the galactosyltransferase I (beta4GalT-7) deficient form of Ehlers-Danlos syndrome. Hum Mol Genet 2008; 17: 996-1009.
26. Fitzgerald DP, Palmieri D, Hua E, et al. Reactive glia are recruited by highly proliferative brain metastases of breast cancer and promote tumor cell colonization. Clin Exp Metastasis 2008; 25: 799-810.
27. Baba F, Swartz K, van Buren R, et al. Syndecan-1 and syndecan-4 are overexpressed in an estrogen receptor-negative, highly proliferative breast carcinoma subtype. Breast Cancer Res Treat 2006; 98: 91-8.
28. Megraw M, Sethupathy P, Corda B, et al. miRGen: a database for the study of animal microRNA genomic organization and function. Nucleic Acids Res 2007; 35: D149-55.
29. Kharabi Masouleh B, Ten Dam GB, Wild MK, et al. Role of the heparan sulfate proteoglycan syndecan-1 (CD138) in delayed-type hypersensitivity. J Immunol 2009; 182: 4985-93.
30. Ashburner M, Ball CA, Blake JA, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 2000; 25: 25-9.
31. Dalmay T, Edwards DR,. MicroRNAs and the hallmarks of cancer. Oncogene 2006; 25: 6170-5.
32. Yang N, Mosher R, Seo S, et al. Syndecan-1 in breast cancer stroma fibroblasts regulates extracellular matrix fiber organization and carcinoma cell motility. Am J Pathol 2011; 178: 325-35.
33. Götte M, Joussen AM, Klein C, et al. Role of syndecan-1 in leukocyte-endothelial interactions in the ocular vasculature. Invest Ophthalmol Vis Sci 2002; 43: 1135-41.
34. Tang Y, Olufemi L, Wang MT, et al. Role of Rho GTPases in breast cancer. Front Biosci 2008; 13: 759-76.
35. Bousquet E, Mazières J, Privat M, et al. Loss of RhoB expression promotes migration and invasion of human bronchial cells via activation of AKT1. Cancer Res 2009; 69: 6092-9.
36. Narumiya S, Tanji M, Ishizaki T,. Rho signaling, ROCK and mDia1, in transformation, metastasis and invasion. Cancer Metastasis Rev 2009; 28: 65-76.
37. Pillé JY, Denoyelle C, Varet J, et al. Anti-RhoA and anti-RhoC siRNAs inhibit the proliferation and invasiveness of MDA-MB-231 breast cancer cells in vitro and in vivo. Mol Ther 2005; 11: 267-74.
38. Liberto M, Cobrinik D, Minden A,. Rho regulates p21(CIP1), cyclin D1, and checkpoint control in mammary epithelial cells. Oncogene 2002; 21: 1590-9.
39. Fujimoto T, Anderson K, Jacobsen SE, et al. Cdk6 blocks myeloid differentiation by interfering with Runx1 DNA binding and Runx1-C/EBPalpha interaction. EMBO J 2007; 26: 2361-70.
40. Liu YN, Lee WW, Wang CY, et al. Regulatory mechanisms controlling human E-cadherin gene expression. Oncogene 2005; 24: 8277-90.
41. Sun L, Gorospe JR, Hoffman EP, et al. Decreased platelet expression of myosin regulatory light chain polypeptide (MYL9) and other genes with platelet dysfunction and CBFA2/RUNX1 mutation: insights from platelet expression profiling. J Thromb Haemost 2007; 5: 146-54.
42. Kopf E, Miskin R,. A RUNX/AML-binding motif residing in a novel 13-bp DNA palindrome may determine the expression of the proximal promoter of the human uPA gene. J Thromb Haemost 2005; 3: 2057-64.
43. Berg T, Fliegauf M, Burger J, et al. Transcriptional upregulation of p21/WAF/Cip1 in myeloid leukemic blasts expressing AML1-ETO. Haematologica 2008; 93: 1728-33.
44. Saoncella S, Calautti E, Neveu W, et al. Syndecan-4 regulates ATF-2 transcriptional activity in a Rac1-dependent manner. J Biol Chem 2004; 279: 47172-6.
45. Koenig A, Mueller C, Hasel C, et al. Collagen type I induces disruption of E-cadherin-mediated cell-cell contacts and promotes proliferation of pancreatic carcinoma cells. Cancer Res 2006; 66: 4662-71.
46. Zimmermann P, Tomatis D, Rosas M, et al. Characterization of syntenin, a syndecan-binding PDZ protein, as a component of cell adhesion sites and microfilaments. Mol Biol Cell 2001; 12: 339-50.
47. Sun L, Yan W, Wang Y, et al. MicroRNA-10b induces glioma cell invasion by modulating MMP-14 and uPAR expression via HOXD10. Brain Res 2011; 1389: 9-18.
48. Rousseau C, Ruellan AL, Bernardeau K, et al. Syndecan-1 antigen, a promising new target for triple-negative breast cancer immuno-PET and radioimmunotherapy. A preclinical study on MDA-MB-468 xenograft tumors. EJNMMI Res 2011; 1: 20.
49. Götte M, Yip GW,. Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective. Cancer Res 2006; 66: 10233-7.
50. Chang YW, Bean RR, Jakobi R,. Targeting RhoA/Rho kinase and p21-activated kinase signaling to prevent cancer development and progression. Recent Pat Anticancer Drug Discov 2009; 4: 110-24.